Evidence map›Paper›PMID 28432476›Full record

ReviewDigestive diseases and sciences2017

Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease.

Esteban Sáez-González, Inés Moret, Diego Alvarez-Sotomayor, Francia Carolina Díaz-Jaime, Elena Cerrillo, Marisa Iborra, Pilar Nos, Belén Beltrán

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05430412 (Clinical Trial to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05430412 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Clinical Trial to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis

TypeinterventionalSponsorAdacyte Therapeutics SLRan2022 to 2024Enrolled15ConditionsUlcerative ColitisArmsAdacolumn
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Esteban Sáez-GonzálezGastroenterology Department, La Fe University and Polytechnic Hospital, Avenida Fernando Abril Martorell 106, 46020, Valencia, Spain. esteban.digestivo@gmail.com.
Inés MoretGastroenterology Department, La Fe University and Polytechnic Hospital, Avenida Fernando Abril Martorell 106, 46020, Valencia, Spain.
Diego Alvarez-SotomayorGastroenterology Department, La Fe University and Polytechnic Hospital, Avenida Fernando Abril Martorell 106, 46020, Valencia, Spain.
Francia Carolina Díaz-JaimeGastroenterology Department, La Fe University and Polytechnic Hospital, Avenida Fernando Abril Martorell 106, 46020, Valencia, Spain.
Elena CerrilloGastroenterology Department, La Fe University and Polytechnic Hospital, Avenida Fernando Abril Martorell 106, 46020, Valencia, Spain.
Marisa IborraGastroenterology Department, La Fe University and Polytechnic Hospital, Avenida Fernando Abril Martorell 106, 46020, Valencia, Spain.
Pilar NosGastroenterology Department, La Fe University and Polytechnic Hospital, Avenida Fernando Abril Martorell 106, 46020, Valencia, Spain.
Belén BeltránGastroenterology Department, La Fe University and Polytechnic Hospital, Avenida Fernando Abril Martorell 106, 46020, Valencia, Spain.
Hospital Universitari i Politècnic La Fe · ESCentro de Investigación Biomédica en Red · ESInstituto de Investigación Sanitaria La Fe · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ulcerative colitis and Crohn's disease are the two main forms of inflammatory bowel disease (IBD). The study of immunological pathways involved in the onset of IBD is of fundamental importance to identify potential biological markers of disease activity and specific targets for therapy. Removing excess and activated circulating leukocytes with adsorptive cytapheresis has been shown to be a potentially effective treatment for patients with an inflamed bowel. Adsorptive cytapheresis is a non-pharmacological approach for active IBD, in which known sources of inflammatory cytokines such as activated myeloid lineage leucocytes are selectively depleted from the circulatory system. The decrease in inflammatory load caused by removing these cells is thought to enhance drug therapy and thereby promote disease remission. The benefit of cytapheresis appears to rest upon its ability to reduce levels of certain immune cell populations; however, whether this depletion results in further changes in lymphocyte populations and cytokine production needs further clarification. In this review, we aim to summarize existing evidence on the role of cytapheresis in patients with IBD, its effect on cytokine levels and cellular populations, and to discuss its potential impact on disease activity.

Indexed as

AdsorptionCytokinesGranulocytesHumansImmunotherapyInflammatory Bowel DiseasesLeukapheresisMonocytesCytokinesCytapheresisCytokinesGranulocyte and monocyte apheresisInflammatory bowel diseaseLeukocytapheresisUlcerative colitis

Identifiers

PMID28432476
OpenAlexW2607090248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.